Case Reports
25 July 2025

Rate of growth of Merkel cell carcinoma: a unique photographic evidence

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
0
Views
0
Downloads

Authors

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin tumor, mainly linked to Merkel Cell Polyomavirus (MCPyV) and less often to ultraviolet exposure. Additional risk factors include advanced age and immunosuppression. Although MCC is known to grow rapidly, its exact growth rate has not been described yet. We report a case of a 73-year-old man who developed de novo MCC on the lower eyelid while undergoing immunotherapy with nivolumab. Clinical photographs document the absence of disease in March 2024 and the appearance of a 7 mm papule in October 2024. Histology confirmed the diagnosis. This case represents rare visual evidence of MCC’s rapid progression, suggesting an estimated growth rate of approximately 1 mm/month. A controversial aspect is that MCC developed despite ongoing treatment with a PD-1 checkpoint inhibitor, currently recommended for this cancer. Although anecdotal, this case highlights MCC’s progression and the need for further research and new therapies.

Altmetrics

Downloads

Download data is not yet available.

Citations

1. Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma. Nat Rev Dis Primer 2017;3:17077.
2. Walsh NM, Cerroni L. Merkel cell carcinoma: A review. J Cutan Pathol 2021;48: 411-21.
3. Nghiem P, Bhatia S, Lipson EJ, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer 2021;9:e002478.
4. Becker JC, Ugurel S, Leiter U, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet 2023;402:798-808.
5. Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol 2020; 38:2476-87.
6. Nammour HM, Madrigal K, Starling CT, Doan HQ. Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies. Int J Mol Sci;2024;25.

How to Cite



Rate of growth of Merkel cell carcinoma: a unique photographic evidence. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10457